115 related articles for article (PubMed ID: 29270413)
21. Aberrant Expression of Cancer Stem Cells Marker Prominin-1 in Low-Grade Tubulolobular Breast Carcinoma: A Correlative Study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis [corrected].
Di Bonito M; Collina F; Cantile M; Camerlingo R; Cerrone M; Marra L; Liguori G; Pirozzi G; Botti G
J Breast Cancer; 2012 Mar; 15(1):15-23. PubMed ID: 22493624
[TBL] [Abstract][Full Text] [Related]
22. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
23. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
24. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
[TBL] [Abstract][Full Text] [Related]
26. Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors.
Morgat C; MacGrogan G; Brouste V; Vélasco V; Sévenet N; Bonnefoi H; Fernandez P; Debled M; Hindié E
J Nucl Med; 2017 Sep; 58(9):1401-1407. PubMed ID: 28280221
[TBL] [Abstract][Full Text] [Related]
27. Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.
Kim TM; Ko YH; Ha SJ; Lee HH
BMC Cancer; 2019 Feb; 19(1):119. PubMed ID: 30717708
[TBL] [Abstract][Full Text] [Related]
28. Nuclear CD133 expression predicts poor prognosis for hepatocellular carcinoma.
Yu GF; Lin X; Luo RC; Fang WY
Int J Clin Exp Pathol; 2018; 11(4):2092-2099. PubMed ID: 31938317
[TBL] [Abstract][Full Text] [Related]
29. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
[TBL] [Abstract][Full Text] [Related]
31. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
33. Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.
Wu H; Guan S; Sun M; Yu Z; Zhao L; He M; Zhao H; Yao W; Wang E; Jin F; Xiao Q; Wei M
PLoS One; 2015; 10(5):e0126128. PubMed ID: 25961581
[TBL] [Abstract][Full Text] [Related]
34. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
35. CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis.
Yiming L; Yunshan G; Bo M; Yu Z; Tao W; Gengfang L; Dexian F; Shiqian C; Jianli J; Juan T; Zhinan C
Oncotarget; 2015 Dec; 6(39):42019-27. PubMed ID: 26503471
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response.
Kronblad A; Jirström K; Rydén L; Nordenskjöld B; Landberg G
Int J Cancer; 2006 May; 118(10):2609-16. PubMed ID: 16381002
[TBL] [Abstract][Full Text] [Related]
37. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
38. Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial.
Goussia A; Simou N; Zagouri F; Manousou K; Lazaridis G; Gogas H; Koutras A; Sotiropoulou M; Pentheroudakis G; Bafaloukos D; Markopoulos C; Patsea H; Christodoulou C; Papakostas P; Zaramboukas T; Samantas E; Kosmidis P; Venizelos V; Karanikiotis C; Papatsibas G; Xepapadakis G; Kalogeras KT; Bamia C; Dimopoulos MA; Malamou-Mitsi V; Fountzilas G; Batistatou A
PLoS One; 2018; 13(7):e0200302. PubMed ID: 30063723
[TBL] [Abstract][Full Text] [Related]
39. Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer.
Hachim IY; Hachim MY; Lopez VM; Lebrun JJ; Ali S
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):238-45. PubMed ID: 26317306
[TBL] [Abstract][Full Text] [Related]
40. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
